HUP0301248A2 - Tiadiazol- és oxadiazolszármazékok, valamint foszfodiészteráz 7-gátlóként való alkalmazásuk - Google Patents

Tiadiazol- és oxadiazolszármazékok, valamint foszfodiészteráz 7-gátlóként való alkalmazásuk

Info

Publication number
HUP0301248A2
HUP0301248A2 HU0301248A HUP0301248A HUP0301248A2 HU P0301248 A2 HUP0301248 A2 HU P0301248A2 HU 0301248 A HU0301248 A HU 0301248A HU P0301248 A HUP0301248 A HU P0301248A HU P0301248 A2 HUP0301248 A2 HU P0301248A2
Authority
HU
Hungary
Prior art keywords
group
heterocycloalkyl
cycloalkenyl
cycloalkyl
optionally substituted
Prior art date
Application number
HU0301248A
Other languages
English (en)
Inventor
Charles Andrianjara
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Original Assignee
Warner-Lambert Co. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Co. Llc filed Critical Warner-Lambert Co. Llc
Publication of HUP0301248A2 publication Critical patent/HUP0301248A2/hu
Publication of HUP0301248A3 publication Critical patent/HUP0301248A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány (I) általános képletű - ahol Y jelentése oxigén- vagykénatom; R1 jelentése alkil-, alkenil-, alkinil-, cikloalkil-,heterocikloalkil-; cikloalkenil-, aril-, heteroaril vagy többgyűrűscsoport, melyek mindegyike adott esetben helyettesített lehet; R2jelentése alkil-, alkenil-, alkinil-, cikloalkil-, heterocikloalkil-,cikloalkenil- vagy arilcsoport, melyek mindegyike adott esetbenhelyettesített lehet; R3 jelentése X2-R'3 általános képletű csoport,melyen belül X2 jelentése kötőcsoport és R'3 jelentése cikloalkil-,heterocikloalkil-, cikloalkenil-, aril-, heteroaril- vagy többgyűrűscsoport, melyek mindegyike adott esetben helyettesített lehet - 1,3,4-tiadiazolokkal, 1,3,4-oxadiazolokkal vagy gyógyászati szempontbólalkalmazható származékaikkal szolgál. Továbbá a találmány foglakozikezek előállítási eljárásaival és a gyógyszerek előállításánál történőfelhasználásukkal, ahol a gyógyszerek olyan betegségek kezelésérehasználhatók, mely kezelésnél a PDE7-gátló alapvető jelentőségűszerepet játszik. Ó
HU0301248A 2000-10-02 2001-10-01 Thiadiazole and oxadiazole derivatives, their use as phosphodiesterase-7 inhibitors HUP0301248A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors
PCT/EP2001/011330 WO2002028847A1 (en) 2000-10-02 2001-10-01 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (2)

Publication Number Publication Date
HUP0301248A2 true HUP0301248A2 (hu) 2003-10-28
HUP0301248A3 HUP0301248A3 (en) 2005-06-28

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301248A HUP0301248A3 (en) 2000-10-02 2001-10-01 Thiadiazole and oxadiazole derivatives, their use as phosphodiesterase-7 inhibitors

Country Status (43)

Country Link
US (1) US7122565B2 (hu)
EP (2) EP1193261A1 (hu)
JP (1) JP4177098B2 (hu)
KR (1) KR100614158B1 (hu)
CN (1) CN1639141A (hu)
AP (1) AP1541A (hu)
AR (1) AR035347A1 (hu)
AT (1) ATE304003T1 (hu)
AU (2) AU2001289945B2 (hu)
BG (1) BG107654A (hu)
BR (1) BR0114391A (hu)
CA (1) CA2424279A1 (hu)
CZ (1) CZ2003857A3 (hu)
DE (1) DE60113283T2 (hu)
DK (1) DK1326853T3 (hu)
DZ (1) DZ3440A1 (hu)
EA (1) EA007179B1 (hu)
EC (1) ECSP034534A (hu)
EE (1) EE200300134A (hu)
ES (1) ES2247166T3 (hu)
GE (1) GEP20053459B (hu)
GT (1) GT200100196A (hu)
HN (1) HN2001000217A (hu)
HR (1) HRP20030247A2 (hu)
HU (1) HUP0301248A3 (hu)
IL (1) IL155122A0 (hu)
IS (1) IS6759A (hu)
MA (1) MA25916A1 (hu)
MX (1) MXPA03002839A (hu)
NO (1) NO20031482L (hu)
NZ (1) NZ524852A (hu)
OA (1) OA12518A (hu)
PA (1) PA8529501A1 (hu)
PE (1) PE20020419A1 (hu)
PL (1) PL366332A1 (hu)
PT (1) PT1326853E (hu)
SI (1) SI1326853T1 (hu)
SK (1) SK3812003A3 (hu)
SV (1) SV2003000633A (hu)
TN (1) TNSN01139A1 (hu)
WO (1) WO2002028847A1 (hu)
YU (1) YU24503A (hu)
ZA (1) ZA200302346B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
RU2376309C2 (ru) 2004-07-01 2009-12-20 Асубио Фарма Ко., Лтд. Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7 (pde 7) активность
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
KR20180011331A (ko) * 2015-06-12 2018-01-31 오리존 지노믹스 에스.에이. Lsd1 억제제와 관련된 바이오마커 및 그의 용도
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (hu)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
US6326378B1 (en) * 1998-02-17 2001-12-04 Roche Diagnostics Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives

Also Published As

Publication number Publication date
CA2424279A1 (en) 2002-04-11
DE60113283D1 (de) 2005-10-13
AU2001289945B2 (en) 2005-12-22
NO20031482D0 (no) 2003-04-01
BG107654A (bg) 2003-12-31
TNSN01139A1 (en) 2005-11-10
GEP20053459B (en) 2005-02-25
IS6759A (is) 2003-03-27
MXPA03002839A (es) 2004-09-10
SI1326853T1 (sl) 2005-12-31
IL155122A0 (en) 2003-10-31
ECSP034534A (es) 2003-07-25
AR035347A1 (es) 2004-05-12
ATE304003T1 (de) 2005-09-15
US20030045557A1 (en) 2003-03-06
MA25916A1 (fr) 2003-10-01
EE200300134A (et) 2003-08-15
CN1639141A (zh) 2005-07-13
PT1326853E (pt) 2005-11-30
PE20020419A1 (es) 2002-07-18
EP1326853B1 (en) 2005-09-07
PL366332A1 (en) 2005-01-24
NZ524852A (en) 2004-09-24
JP2004510769A (ja) 2004-04-08
EA200300333A1 (ru) 2003-10-30
AP2003002764A0 (en) 2003-03-31
KR100614158B1 (ko) 2006-08-21
EP1326853A1 (en) 2003-07-16
HRP20030247A2 (en) 2005-04-30
ES2247166T3 (es) 2006-03-01
PA8529501A1 (es) 2003-06-30
JP4177098B2 (ja) 2008-11-05
WO2002028847A1 (en) 2002-04-11
EP1193261A1 (en) 2002-04-03
ZA200302346B (en) 2004-08-04
SV2003000633A (es) 2003-04-03
HN2001000217A (es) 2002-06-13
BR0114391A (pt) 2003-06-24
US7122565B2 (en) 2006-10-17
GT200100196A (es) 2002-07-18
SK3812003A3 (en) 2004-05-04
AP1541A (en) 2006-01-11
HUP0301248A3 (en) 2005-06-28
CZ2003857A3 (cs) 2004-02-18
EA007179B1 (ru) 2006-08-25
DK1326853T3 (da) 2005-12-12
OA12518A (en) 2006-05-29
DZ3440A1 (fr) 2002-04-11
DE60113283T2 (de) 2006-06-08
KR20030068542A (ko) 2003-08-21
AU8994501A (en) 2002-04-15
YU24503A (sh) 2006-03-03
NO20031482L (no) 2003-04-01

Similar Documents

Publication Publication Date Title
HUP0301248A2 (hu) Tiadiazol- és oxadiazolszármazékok, valamint foszfodiészteráz 7-gátlóként való alkalmazásuk
HUP0401478A2 (hu) Fungicid hatású pirazolil-karboxanilid-származékok
HUP0302955A2 (hu) HMG-CoA reduktáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk koleszterinnel kapcsolatos betegségek kezelésére
HUP0400451A2 (hu) Pirrolszármazékok és ezeket tartalmazó gyógyászati készítmények
HUP0301660A2 (hu) Neutrális endropeptidáz inhibitor (NEPI) vegyületek alkalmazása férfi szexuális mżködési zavar kezelésére és az azokat tartalmazó gyógyszerkészítmények
ES2187473T3 (es) Triarylimidazoles.
HUP0400202A2 (hu) Metalloproteináz inhibitor, hatású imidazolidin-dion-származékok alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
IS2833B (is) 1,5 Bensóþíósepín og notkun þeirra gegn fitublæði
HUP0202623A2 (hu) MEK-gátló vegyületek alkalmazása gyógyászati készítmények előállítására
HUP0002050A2 (hu) Szubsztituált imidazolvegyületek, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0303391A2 (hu) Alifás, nitrogéntartalmú 5-tagú gyűrűs vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE0102616D0 (sv) Novel compounds
ATE372767T1 (de) Dpp-iv-hemmer
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
HUP0400240A2 (hu) Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények
HUP0401488A2 (hu) Fungicid hatású 7-amino-triazolopirimidinek, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
IL171977A0 (en) Cyclic sulfonamides for inhibition of gamma-secretase
HUP0000965A2 (hu) Foszfolipáz A2 inhibitor hatású pirrolidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
DK0982992T3 (da) Anvendelse af thienopyrimidiner som fungicider
HUP0204501A2 (hu) Gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására és alkalmazásuk
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer